Filing Details

Accession Number:
0001209191-20-045935
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-10 16:19:44
Reporting Period:
2020-08-06
Accepted Time:
2020-08-10 16:19:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1735944 Reshma Kewalramani C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Ceo & President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-06 1,564 $187.53 28,190 No 4 M Direct
Common Stock Acquisiton 2020-08-06 509 $155.57 28,699 No 4 M Direct
Common Stock Disposition 2020-08-06 152 $269.11 28,547 No 4 S Direct
Common Stock Disposition 2020-08-06 870 $270.36 27,677 No 4 S Direct
Common Stock Disposition 2020-08-06 471 $271.42 27,206 No 4 S Direct
Common Stock Disposition 2020-08-06 487 $272.76 26,719 No 4 S Direct
Common Stock Disposition 2020-08-06 93 $273.27 26,626 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-08-06 1,564 $0.00 1,564 $187.53
Common Stock Stock Option (Right to Buy) Disposition 2020-08-06 509 $0.00 509 $155.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,642 2029-02-05 No 4 M Direct
3,058 2028-02-05 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $269.11 (range $268.69 to $269.59).
  3. Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $270.36 (range $269.90 to $270.85).
  5. Open market sales reported on this line occurred at a weighted average price of $271.42 (range $270.97 to $271.88).
  6. Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.25 to $272.99).
  7. The option vests in 16 quarterly installments from 02/06/2019.
  8. The option vests in 16 quarterly installments from 02/06/2018.